vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与Syndax Pharmaceuticals Inc（SNDX）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是Syndax Pharmaceuticals Inc的1.1倍（$75.5M vs $68.5M），Syndax Pharmaceuticals Inc同比增速更快（791.7% vs 27.7%）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
Syndax Pharmaceuticals是一家临床阶段生物制药企业，专注于为难治性癌症患者开发创新肿瘤疗法，旗下产品线涵盖靶向药物及免疫疗法候选产品，致力于解决未被满足的临床需求，服务全球肿瘤诊疗领域相关从业者及患者群体。
PBYI vs SNDX — 直观对比
营收规模更大
PBYI
是对方的1.1倍
$68.5M
营收增速更快
SNDX
高出764.0%
27.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $68.5M |
| 净利润 | — | $-68.0M |
| 毛利率 | 69.3% | — |
| 营业利润率 | 22.7% | -91.3% |
| 净利率 | — | -99.3% |
| 营收同比 | 27.7% | 791.7% |
| 净利润同比 | — | 27.8% |
| 每股收益（稀释后） | $0.26 | $-0.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYISNDX
| Q4 25 | $75.5M | $68.5M | ||
| Q3 25 | $54.5M | $45.9M | ||
| Q2 25 | $52.4M | $38.0M | ||
| Q1 25 | $46.0M | $20.0M | ||
| Q4 24 | $59.1M | — | ||
| Q3 24 | $80.5M | $12.5M | ||
| Q2 24 | $47.1M | — | ||
| Q1 24 | $43.8M | $0 |
净利润PBYISNDX
| Q4 25 | — | $-68.0M | ||
| Q3 25 | $8.8M | $-60.7M | ||
| Q2 25 | $5.9M | $-71.8M | ||
| Q1 25 | $3.0M | $-84.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $20.3M | $-84.1M | ||
| Q2 24 | $-4.5M | — | ||
| Q1 24 | $-4.8M | $-72.4M |
毛利率PBYISNDX
| Q4 25 | 69.3% | — | ||
| Q3 25 | 77.7% | — | ||
| Q2 25 | 76.5% | — | ||
| Q1 25 | 77.1% | — | ||
| Q4 24 | 76.4% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 77.4% | — | ||
| Q1 24 | 75.5% | — |
营业利润率PBYISNDX
| Q4 25 | 22.7% | -91.3% | ||
| Q3 25 | 17.6% | -125.2% | ||
| Q2 25 | 12.7% | -182.7% | ||
| Q1 25 | 8.7% | -417.9% | ||
| Q4 24 | 22.6% | — | ||
| Q3 24 | 27.4% | -716.6% | ||
| Q2 24 | -4.6% | — | ||
| Q1 24 | -5.3% | — |
净利率PBYISNDX
| Q4 25 | — | -99.3% | ||
| Q3 25 | 16.2% | -132.4% | ||
| Q2 25 | 11.2% | -189.3% | ||
| Q1 25 | 6.5% | -423.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | -673.0% | ||
| Q2 24 | -9.6% | — | ||
| Q1 24 | -11.0% | — |
每股收益（稀释后）PBYISNDX
| Q4 25 | $0.26 | $-0.78 | ||
| Q3 25 | $0.17 | $-0.70 | ||
| Q2 25 | $0.12 | $-0.83 | ||
| Q1 25 | $0.06 | $-0.98 | ||
| Q4 24 | $0.40 | — | ||
| Q3 24 | $0.41 | $-0.98 | ||
| Q2 24 | $-0.09 | — | ||
| Q1 24 | $-0.10 | $-0.85 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | $394.1M |
| 总债务越低越好 | $22.7M | — |
| 股东权益账面价值 | $130.3M | $64.6M |
| 总资产 | $216.3M | $529.7M |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资PBYISNDX
| Q4 25 | $97.5M | $394.1M | ||
| Q3 25 | $94.4M | $436.0M | ||
| Q2 25 | $96.0M | $455.2M | ||
| Q1 25 | $93.2M | $512.2M | ||
| Q4 24 | $101.0M | — | ||
| Q3 24 | $96.7M | $389.6M | ||
| Q2 24 | $96.8M | — | ||
| Q1 24 | $107.2M | $434.6M |
总债务PBYISNDX
| Q4 25 | $22.7M | — | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $45.3M | — | ||
| Q1 25 | $56.7M | — | ||
| Q4 24 | $68.0M | — | ||
| Q3 24 | $79.3M | — | ||
| Q2 24 | $90.7M | — | ||
| Q1 24 | $102.0M | — |
股东权益PBYISNDX
| Q4 25 | $130.3M | $64.6M | ||
| Q3 25 | $115.3M | $115.4M | ||
| Q2 25 | $104.7M | $157.4M | ||
| Q1 25 | $97.1M | $215.1M | ||
| Q4 24 | $92.1M | — | ||
| Q3 24 | $71.1M | $366.4M | ||
| Q2 24 | $48.5M | — | ||
| Q1 24 | $51.0M | $491.9M |
总资产PBYISNDX
| Q4 25 | $216.3M | $529.7M | ||
| Q3 25 | $202.9M | $551.8M | ||
| Q2 25 | $194.9M | $596.1M | ||
| Q1 25 | $196.2M | $640.7M | ||
| Q4 24 | $213.3M | — | ||
| Q3 24 | $220.7M | $425.8M | ||
| Q2 24 | $205.0M | — | ||
| Q1 24 | $214.1M | $543.0M |
负债/权益比PBYISNDX
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | 2.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $-69.5M |
| 自由现金流经营现金流 - 资本支出 | $14.4M | — |
| 自由现金流率自由现金流/营收 | 19.1% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $41.7M | — |
8季度趋势，按日历期对齐
经营现金流PBYISNDX
| Q4 25 | $14.4M | $-69.5M | ||
| Q3 25 | $9.7M | $-70.5M | ||
| Q2 25 | $14.1M | $-87.8M | ||
| Q1 25 | $3.6M | $-95.2M | ||
| Q4 24 | $15.6M | — | ||
| Q3 24 | $11.0M | $-62.3M | ||
| Q2 24 | $1.0M | — | ||
| Q1 24 | $11.2M | $-83.5M |
自由现金流PBYISNDX
| Q4 25 | $14.4M | — | ||
| Q3 25 | $9.7M | — | ||
| Q2 25 | $14.1M | — | ||
| Q1 25 | $3.6M | — | ||
| Q4 24 | $15.6M | — | ||
| Q3 24 | $11.0M | — | ||
| Q2 24 | $1.0M | — | ||
| Q1 24 | — | — |
自由现金流率PBYISNDX
| Q4 25 | 19.1% | — | ||
| Q3 25 | 17.7% | — | ||
| Q2 25 | 26.8% | — | ||
| Q1 25 | 7.7% | — | ||
| Q4 24 | 26.4% | — | ||
| Q3 24 | 13.7% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | — | — |
资本支出强度PBYISNDX
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
现金转化率PBYISNDX
| Q4 25 | — | — | ||
| Q3 25 | 1.10× | — | ||
| Q2 25 | 2.41× | — | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
